About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials in Dallas | 461 Studies

Clinical Trials Lung CancerDallas

Lung Cancer Clinical Trials in Dallas

Find 461 clinical trials for lung cancer near Dallas, Texas. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Dallas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 461 trials

CompletedA Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentThis open-label, non-randomized, multicenter, Phase 1/2 study will evaluate the safety and efficacy of alectinib in participants with non-small cell lung cancer who have ALK…NCT01801111·Birmingham, Alabama and 83 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

No longer availableExpanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 PositiveThis expanded access study has being designed following a demand from the FDA, given the increase in the number of request for single patient INDs for lorlatinibNCT03178071·Sedona, Arizona and 48 others

CompletedTaxoprexin Plus Carboplatin Treatment for Advanced Lung CancerThe primary objective of this trial is to compare the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with…NCT00243867·Dallas, Texas

RecruitingA Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsCancer is a condition where cells in a specific part of body grow and reproduce uncontrollably.NCT07241039·Duarte, California and 12 others

CompletedTrial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced CancerAutologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid.NCT01061840·West Palm Beach, Florida and 3 others

Active not recruitingA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022.NCT02817633·Goodyear, Arizona and 88 others

RecruitingOsimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerThis phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside…NCT04181060·Anchorage, Alaska and 602 others

CompletedStudy of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerThe purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.NCT00080340·Birmingham, Alabama and 337 others

CompletedStudy of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)* The study is evaluating the safety and tolerability of Nivolumab (BMS-936558) when combined with three platinum-based doublet chemotherapy regimens (Cisplatin/Gemcitabine…NCT01454102·Los Angeles, California and 11 others

CompletedCarboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung CancerRATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.NCT00070486·Anniston, Alabama and 74 others

CompletedVinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically RemovedRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00002583·Birmingham, Alabama and 154 others

CompletedCisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00017459·Los Angeles, California and 41 others

TerminatedTIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed TherapyThe purpose of this study is to compare the safety and anti-tumor effect of rociletinib with erlotinib in patients whose tumors have specific EGFR mutations and who have not…NCT02186301·Birmingham, Alabama and 73 others

RecruitingPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with…NCT04613596·Goodyear, Arizona and 769 others

CompletedA Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid TumorsTo better understand the safety and tolerability of ALKS 4230 in humansNCT02799095·Denver, Colorado and 30 others

CompletedA Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus…NCT04623775·Duarte, California and 124 others

RecruitingFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCThe purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best…NCT06303505·Birmingham, Alabama and 28 others

RecruitingA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor…NCT06452277·Newport Beach, California and 278 others

CompletedSafety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as…NCT03829319·Mountain View, California and 157 others

RecruitingA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPhase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2…NCT03093116·Duarte, California and 164 others

Page 1 of 24Next

Other Conditions in Dallas

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma